Cargando…
Computational drug repositioning using meta-path-based semantic network analysis
BACKGROUND: Drug repositioning is a promising and efficient way to discover new indications for existing drugs, which holds the great potential for precision medicine in the post-genomic era. Many network-based approaches have been proposed for drug repositioning based on similarity networks, which...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311940/ https://www.ncbi.nlm.nih.gov/pubmed/30598084 http://dx.doi.org/10.1186/s12918-018-0658-7 |
_version_ | 1783383706311852032 |
---|---|
author | Tian, Zhen Teng, Zhixia Cheng, Shuang Guo, Maozu |
author_facet | Tian, Zhen Teng, Zhixia Cheng, Shuang Guo, Maozu |
author_sort | Tian, Zhen |
collection | PubMed |
description | BACKGROUND: Drug repositioning is a promising and efficient way to discover new indications for existing drugs, which holds the great potential for precision medicine in the post-genomic era. Many network-based approaches have been proposed for drug repositioning based on similarity networks, which integrate multiple sources of drugs and diseases. However, these methods may simply view nodes as the same-typed and neglect the semantic meanings of different meta-paths in the heterogeneous network. Therefore, it is urgent to develop a rational method to infer new indications for approved drugs. RESULTS: In this study, we proposed a novel methodology named HeteSim_DrugDisease (HSDD) for the prediction of drug repositioning. Firstly, we build the drug-drug similarity network and disease-disease similarity network by integrating the information of drugs and diseases. Secondly, a drug-disease heterogeneous network is constructed, which combines the drug similarity network, disease similarity network as well as the known drug-disease association network. Finally, HSDD predicts novel drug-disease associations based on the HeteSim scores of different meta-paths. The experimental results show that HSDD performs significantly better than the existing state-of-the-art approaches. HSDD achieves an AUC score of 0.8994 in the leave-one-out cross validation experiment. Moreover, case studies for selected drugs further illustrate the practical usefulness of HSDD. CONCLUSIONS: HSDD can be an effective and feasible way to infer the associations between drugs and diseases using on meta-path-based semantic network analysis. |
format | Online Article Text |
id | pubmed-6311940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63119402019-01-07 Computational drug repositioning using meta-path-based semantic network analysis Tian, Zhen Teng, Zhixia Cheng, Shuang Guo, Maozu BMC Syst Biol Research BACKGROUND: Drug repositioning is a promising and efficient way to discover new indications for existing drugs, which holds the great potential for precision medicine in the post-genomic era. Many network-based approaches have been proposed for drug repositioning based on similarity networks, which integrate multiple sources of drugs and diseases. However, these methods may simply view nodes as the same-typed and neglect the semantic meanings of different meta-paths in the heterogeneous network. Therefore, it is urgent to develop a rational method to infer new indications for approved drugs. RESULTS: In this study, we proposed a novel methodology named HeteSim_DrugDisease (HSDD) for the prediction of drug repositioning. Firstly, we build the drug-drug similarity network and disease-disease similarity network by integrating the information of drugs and diseases. Secondly, a drug-disease heterogeneous network is constructed, which combines the drug similarity network, disease similarity network as well as the known drug-disease association network. Finally, HSDD predicts novel drug-disease associations based on the HeteSim scores of different meta-paths. The experimental results show that HSDD performs significantly better than the existing state-of-the-art approaches. HSDD achieves an AUC score of 0.8994 in the leave-one-out cross validation experiment. Moreover, case studies for selected drugs further illustrate the practical usefulness of HSDD. CONCLUSIONS: HSDD can be an effective and feasible way to infer the associations between drugs and diseases using on meta-path-based semantic network analysis. BioMed Central 2018-12-31 /pmc/articles/PMC6311940/ /pubmed/30598084 http://dx.doi.org/10.1186/s12918-018-0658-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tian, Zhen Teng, Zhixia Cheng, Shuang Guo, Maozu Computational drug repositioning using meta-path-based semantic network analysis |
title | Computational drug repositioning using meta-path-based semantic network analysis |
title_full | Computational drug repositioning using meta-path-based semantic network analysis |
title_fullStr | Computational drug repositioning using meta-path-based semantic network analysis |
title_full_unstemmed | Computational drug repositioning using meta-path-based semantic network analysis |
title_short | Computational drug repositioning using meta-path-based semantic network analysis |
title_sort | computational drug repositioning using meta-path-based semantic network analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311940/ https://www.ncbi.nlm.nih.gov/pubmed/30598084 http://dx.doi.org/10.1186/s12918-018-0658-7 |
work_keys_str_mv | AT tianzhen computationaldrugrepositioningusingmetapathbasedsemanticnetworkanalysis AT tengzhixia computationaldrugrepositioningusingmetapathbasedsemanticnetworkanalysis AT chengshuang computationaldrugrepositioningusingmetapathbasedsemanticnetworkanalysis AT guomaozu computationaldrugrepositioningusingmetapathbasedsemanticnetworkanalysis |